Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  De Langhe, Sofie ^a   Mulliez, Thomas ^b   Veldeman, Liv ^b   Remouchamps, Vincent ^c   van Greveling, Annick ^b   Gilsoul, Monique ^c   De Schepper, Eline ^a   De Ruyck, Kim ^a   De Neve, Wilfried ^b   Thierens, Hubert ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Clinique et Maternité St Elisabeth   (Belgium)

Author keywords

Acute skin toxicity; Breast cancer; Genetic polymorphisms; Large breast size; Radiotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BELGIUM; BODY MASS; BODY POSTURE; BRA CUP SIZE; BREAST CANCER; BREAST SIZE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIG3 GENE; MAJOR CLINICAL STUDY; MLH1 GENE; PARTIAL MASTECTOMY; PROTECTION; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN EXFOLIATION; SKIN TOXICITY; SMOKING; SUPINE POSITION; UNIVERSITY HOSPITAL; XRCC3 GENE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; RADIODERMATITIS; RISK FACTOR; SEGMENTAL MASTECTOMY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIODERMATITIS; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84907677589     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-711     Document Type: Article

References (31)

1. Early Breast Canc Trialists C Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716. 3254252, 22019144, Early Breast Canc Trialists C.
2. Feight D, Baney T, Bruce S, McQuestion M. Putting evidence into practice: evidence-based interventions for radiation dermatitis. Clin J Oncol Nurs 2011, 15(5):481-492. 10.1188/11.CJON.481-492, 21951735.
3. Tanteles GA, Whitworth J, Mills J, Peat I, Osman A, McCann GP, Chan S, Barwell JG, Talbot CJ, Symonds RP. Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?. Br J Cancer 2009, 101(3):403-409. 10.1038/sj.bjc.6605182, 2720242, 19603028.
4. Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat 2007, 106(1):143-150. 10.1007/s10549-006-9480-9, 17221151.
5. Keller LMM, Sopka DM, Li TY, Klayton T, Li JS, Anderson PR, Bleicher RJ, Sigurdson ER, Freedman GM. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the fox chase cancer center experience. Int J Radiat Oncol Biol Phys 2012, 84(4):881-887. 10.1016/j.ijrobp.2012.01.069, 22909414.
6. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Vu TTT, Truong P, Ackerman I, Paszat L. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008, 26(13):2085-2092. 10.1200/JCO.2007.15.2488, 18285602.
7. Freedman GM, Anderson PR, Li JS, Eisenberg DF, Hanlon AL, Wang L, Nicolaou N. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol-Cancer Clinical Trials 2006, 29(1):66-70.
8. Moody AM, Mayles WPM, Bliss JM, Ahern RP, Owen JR, Regan J, Broad B, Yarnold JR. The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol 1994, 33(2):106-112. 10.1016/0167-8140(94)90063-9, 7708953.
9. Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJS, Popanda O, Seibold P, West CML, Yarnold JR, Symonds RP. A replicated association between polymorphisms near TNF alpha and risk for adverse reactions to radiotherapy. Br J Cancer 2012, 107(4):748-753. 10.1038/bjc.2012.290, 3419947, 22767148.
10. Kim JH, Kolozsvary AJJ, Jenrow KA, Brown SL. Mechanisms of radiation-induced skin injury and implications for future clinical trials. Int J Radiat Biol 2013, 89(5):311-318. 10.3109/09553002.2013.765055, 23305180.
11. Rosenstein BS. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011, 12(2):267-275. 10.2217/pgs.10.186, 3128821, 21332318.
12. Murray RJS, Tanteles GA, Mills J, Perry A, Peat I, Osman A, Chan S, Cheung KL, Chakraborti PR, Woodings PL, Barwell JG, Symonds RP, Talbot CJ. Association between single nucleotide polymorphisms in the DNA repair gene LIG3 and acute adverse skin reactions following radiotherapy. Radiother Oncol 2011, 99(2):231-234. 10.1016/j.radonc.2011.05.007, 21620500.
13. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, Omura M, Sekiguchi K, Kikuchi Y, Michikawa Y, Noda S, Sagara M, Ohashi J, Yoshinaga S, Mizoe J, Tsuiti H, Iwakawa M, Imai T. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69(3):685-693. 10.1016/j.ijrobp.2007.06.021, 17889263.
14. Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H. Acute normal tissue reactions in head-and-neck cancer patients treated with Imrt: influence of dose and association with genetic polymorphisms in DNA Dsb repair genes. Int J Radiat Oncol Biol Phys 2009, 73(4):1187-1195. 10.1016/j.ijrobp.2008.08.073, 19251090.
15. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008, 45(3):142-146. 4022773, 17959715.
16. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of radiation-induced changes in human gene expression. Nature 2009, 459(7246):587-U120. 10.1038/nature07940, 3005325, 19349959.
17. Mulliez T, Speleers B, Madani I, De Gersem W, Veldeman L, De Neve W. Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT?. Radiat Oncol 2013, 8:151. 10.1186/1748-717X-8-151, 3702403, 23800109.
18. Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DAL, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR, Start Trialists G. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371(9618):1098-1107. 2277488, 18355913.
19. Mulliez T, Veldeman L, van Greveling A, Speleers B, Sadeghi S, Berwouts D, Decoster F, Vercauteren T, De Gersem W, Van den Broecke R, De Neve W. Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone and supine positions. Radiother Oncol 2013, 108(2):203-208. 10.1016/j.radonc.2013.08.040, 24044803.
20. Remouchamps VM, Vicini FA, Sharpe MB, Kestin LL, Martinez AA, Wong JW. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2003, 55(2):392-406. 10.1016/S0360-3016(02)04143-3, 12527053.
21. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008, 9:36. 2387159, 18477402.
22. James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 2010, (11):CD003860.
23. Hannan R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen CC, Landau E, Miller E, Spierer M, Hong L, Kalnicki S. Hypofractionated whole-breast radiation therapy: does breast size matter?. Int J Radiat Oncol Biol Phys 2012, 84(4):894-901. 10.1016/j.ijrobp.2012.01.093, 22543209.
24. Corbin KS, Dorn PL, Jain SK, Al-Hallaq HA, Hasan Y, Chmura SJ. Hypofractionated radiotherapy does not increase acute toxicity in large-breasted women: results from a prospectively collected series. Am J Clin Oncol 2014, 37(4):322-326. 10.1097/COC.0b013e31827b45b7, 23357972.
25. Goldsmith C, Haviland J, Tsang Y, Sydenham M, Yarnold J, Grp FT. Large breast size as a risk factor for late adverse effects of breast radiotherapy: Is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?. Radiother Oncol 2011, 100(2):236-240. 10.1016/j.radonc.2010.12.012, 21296441.
26. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE. The cambridge breast intensity-modulated radiotherapy trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol 2011, 23(10):662-673.
27. Dorn PL, Corbin KS, Al-Hallaq H, Hasan Y, Chmura SJ. Feasibility and acute toxicity of hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys 2012, 83(1):79-83. 10.1016/j.ijrobp.2011.05.074, 22035661.
28. Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NEA, Ozsahin M. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010, 11(3):258-265. 10.1016/S1470-2045(10)70013-9, 20138810.
29. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009, 27(16):2638-2644. 10.1200/JCO.2008.17.9549, 2690390, 19349549.
30. Whiffin N, Broderick P, Lubbe SJ, Pittman AM, Penegar S, Chandler I, Houlston RS. MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis 2011, 32(8):1157-1161. 10.1093/carcin/bgr089, 21565826.
31. Janko M, Ontiveros F, Fitzgerald TJ, Deng A, DeCicco M, Rock KL. IL-1 Generated subsequent to radiation-induced tissue injury contributes to the pathogenesis of radiodermatitis. Int J Radiat Oncol Biol Phys 2012, 84(3):S679-S679.